Marc Spentchian
Le Chesnay, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
Journal: Haematologica
Published: September 17, 2021
Nivolumab to control molecular response in chronic myeloid leukemia.
Journal: Leukemia research
Published: June 07, 2018
High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations.
Journal: Scientific reports
Published: February 02, 2018
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
Journal: Leukemia & lymphoma
Published: November 29, 2017
Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.
Journal: Blood cancer journal
Published: September 20, 2014
Reply to J. Richter et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2014
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Journal: Nature
Published: March 17, 2014
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 11, 2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 22, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026